Back to Search
Start Over
The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
- Source :
- Cancer Medicine
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- The European Treatment and Outcome Study (EUTOS) long‐term survival (ELTS) score predicts disease‐specific death in patients with chronic myeloid leukemia (CML) being treated with imatinib during the chronic phase (CP) of the disease. However, it is unclear whether the ELTS score predicts CML‐related events or treatment responses. This study evaluated the predictive value of the ELTS score regarding prognosis and treatment response in patients with CML‐CP. Clinical data were retrospectively obtained from patients enrolled in the CML Cooperative Study Group (CML‐CSG), which included patients diagnosed with CML‐CP from April 2001 to January 2016, and treated with any tyrosine kinase inhibitor (TKI) as first‐line therapy. Among 342 eligible patients, the ELTS scores indicated low‐, intermediate‐, and high‐risk in 74%, 21%, and 5% of patients, respectively. Patients with high ELTS scores had significantly higher disease‐specific mortality and worse event‐free survival, progression‐free survival, and overall survival. Among four risk scores, including the Sokal, Hasford, EUTOS, and ELTS scores, risk stratification by the ELTS score had the highest predictive value in assessing patient prognosis, and also in treatment responses. In fact, the EUTOS and ELTS scores were able to predict the major molecular response within 12 months. Most importantly, the ELTS score was the only scoring system that predicted deep molecular response at any time, regardless of risk level (65.0%, 43.7%, and 23.5% in low‐, intermediate‐, and high‐risk groups, respectively). Compared to other risk scores, the ELTS score was the most sensitive risk classification tool for the four endpoints of interest in this study, as well as molecular responses in patients with CML‐CP.<br />In this real‐world TKIs treated CML‐CP patients cohort, the EUTOS long‐term survival (ELTS) score was the most sensitive risk classification tool to predict CML‐specific deaths, EFS, PFS, and OS compared to the Sokal, Hasford, and EUTOS scoring systems. Notably, the ELTS score was the only scoring system that predicted cumulative incidence of deep molecular response.
- Subjects :
- Male
0301 basic medicine
Cancer Research
Time Factors
Fusion Proteins, bcr-abl
Disease
Tyrosine-kinase inhibitor
tyrosine kinase inhibitor
0302 clinical medicine
Japan
Risk Factors
hemic and lymphatic diseases
Registries
Original Research
Aged, 80 and over
Age specific mortality
Myeloid leukemia
Middle Aged
Progression-Free Survival
Oncology
030220 oncology & carcinogenesis
Cohort
Disease Progression
Imatinib Mesylate
Female
medicine.drug
Adult
medicine.medical_specialty
Treatment response
Adolescent
medicine.drug_class
Antineoplastic Agents
Risk Assessment
Decision Support Techniques
Young Adult
03 medical and health sciences
Predictive Value of Tests
chronic myeloid leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Internal medicine
Long term survival
Biomarkers, Tumor
medicine
Humans
Radiology, Nuclear Medicine and imaging
Protein Kinase Inhibitors
Aged
Retrospective Studies
ELTS score
business.industry
Clinical Cancer Research
Imatinib
030104 developmental biology
prognosis
business
EUTOS
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....d7648cbe2bcf035e55abe174ff7d1709
- Full Text :
- https://doi.org/10.1002/cam4.3516